International journal of radiation oncology, biology, physics 2014-04-01
Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Abstract
Purpose
We extended our previous experience with stereotactic ablative radiation therapy (SABR; 50 Gy in 4 fractions) for centrally located non-small cell lung cancer (NSCLC); explored the use of 70 Gy in 10 fractions for cases in which dose-volume constraints could not be met with the previous regimen; and suggested modified dose-volume constraints.
Methods and materials
Four-dimensional computed tomography (4DCT)-based volumetric image-guided SABR was used for 100 patients with biopsy-proven, central T1-T2N0M0 (n=81) or isolated parenchymal recurrence of NSCLC (n=19). All disease was staged with positron emission tomography/CT; all tumors were within 2 cm of the bronchial tree, trachea, major vessels, esophagus, heart, pericardium, brachial plexus, or vertebral body. Endpoints were toxicity, overall survival (OS), local and regional control, and distant metastasis.
Results
At a median follow-up time of 30.6 months, median OS time was 55.6 months, and the 3-year OS rate was 70.5%. Three-year cumulative actuarial local, regional, and distant control rates were 96.5%, 87.9%, and 77.2%, respectively. The most common toxicities were chest-wall pain (18% grade 1, 13% grade 2) and radiation pneumonitis (11% grade 2 and 1% grade 3). No patient experienced grade 4 or 5 toxicity. Among the 82 patients receiving 50 Gy in 4 fractions, multivariate analyses showed mean total lung dose >6 Gy, V20 >12%, or ipsilateral lung V30 >15% to independently predict radiation pneumonitis; and 3 of 9 patients with brachial plexus Dmax >35 Gy experienced brachial neuropathy versus none of 73 patients with brachial Dmax <35 Gy (P=.001). Other toxicities were analyzed and new dose-volume constraints are proposed.
Conclusions
SABR for centrally located lesions produces clinical outcomes similar to those for peripheral lesions when normal tissue constraints are respected.
Related Questions
Do you ever consider small vessel doses when determining your dose for SBRT?
We do not constraint dose to the azygous vein, or other small vessels when giving SBRT. We similarly do not constrain dose to large vessels such as the IVC or the Aorta either, and I am un-aware of specific reports of toxicity to these structures. Structures that I am particularly concerned about ar...
What is your preferred dose and fractionation schedule for a patient with a stage III non-small cell lung cancer, whose comorbidities preclude chemotherapy, but has good enough performance status to warrant an attempt at longer-term local control?
This is a very good question. I'd say the answer to this one is evolving! Typically the patients who cannot tolerate either sequential or concurrent chemotherapy for locally-advanced NSCLC are quite frail and/or have comorbidities that are significant. The results using radiation alone for Stage III...
What is the optimal treatment of medically inoperable T3N0 non-small cell lung cancer that is too large for standard SBRT?
As we see it, there is more than one way to skin the cat. RTOG 0617 has condemned protracted fractions to 70 Gy...it just might be that 70 Gy is the wrong way to treat in 35 fractions, +/- cetuximab added to weakly carbo taxol. But the study to look at thoracic dose is contaminated by those systemic...
What is an acceptable distance between tumor and heart or aorta to treat a non-small cell lung cancer with SBRT?
I will echo @Dr. First Last's answer. Having used 50 Gy in 5 fractions now for over 10 years at the Cleveland Clinic, we have not identified cardiac or great vessel specific toxicities for the close to 400 patients we have treated with this schedule. Specifically in compiling our data registry, we h...